Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances...
PR Newswire
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing...
PR Newswire
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 31, 2026 Company to host a corporate update call Tuesday, September 1st at...
PR Newswire
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 28, 2026 SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the...
PR Newswire
Kazia Therapeutics Limited Announces Proposed Public Offering
Kazia Therapeutics Limited Announces Proposed Public Offering Kazia Therapeutics Limited Announces Proposed Public Offering PR Newswire SYDNEY, Aug. 27, 2026 SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology...
PR Newswire
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer PR Newswire SYDNEY, Aug. 27, 2026 Durable...
PR Newswire
The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers
Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX
24-7 Market News
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Kazia Therapeutics Appoints James Levine as Chief Financial Officer Kazia Therapeutics Appoints James Levine as Chief Financial Officer PR Newswire SYDNEY, June 2, 2026 SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a...
PR Newswire
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire SYDNEY, May 26, 2026 Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging...
PR Newswire
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform Kazia Therapeutics Strengthens Scientific...
PR Newswire